Nurix Therapeutics, Inc. (NASDAQ:NRIX) Position Lessened by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc decreased its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 55.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,644 shares of the company’s stock after selling 44,263 shares during the period. Ensign Peak Advisors Inc owned 0.07% of Nurix Therapeutics worth $744,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after purchasing an additional 3,424 shares during the last quarter. EntryPoint Capital LLC bought a new stake in shares of Nurix Therapeutics in the 1st quarter worth approximately $123,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after purchasing an additional 3,793 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Nurix Therapeutics by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after purchasing an additional 998 shares during the last quarter. Finally, Arizona State Retirement System bought a new stake in Nurix Therapeutics during the 2nd quarter valued at $295,000.

Nurix Therapeutics Stock Down 0.7 %

Shares of NASDAQ NRIX opened at $23.05 on Friday. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -7.89 and a beta of 2.23. The stock’s fifty day simple moving average is $23.14 and its 200 day simple moving average is $18.63. Nurix Therapeutics, Inc. has a 52-week low of $4.22 and a 52-week high of $26.31.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). The company had revenue of $12.09 million during the quarter, compared to analyst estimates of $19.35 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. As a group, analysts anticipate that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Gwenn Hansen sold 3,408 shares of Nurix Therapeutics stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $70,443.36. Following the transaction, the insider now directly owns 45,150 shares in the company, valued at approximately $933,250.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Gwenn Hansen sold 3,408 shares of Nurix Therapeutics stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $70,443.36. Following the transaction, the insider now owns 45,150 shares in the company, valued at $933,250.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the transaction, the chief financial officer now owns 54,479 shares in the company, valued at approximately $1,126,080.93. The disclosure for this sale can be found here. Insiders have sold 59,815 shares of company stock worth $1,416,751 in the last three months. 7.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on NRIX shares. JPMorgan Chase & Co. lifted their target price on Nurix Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. Royal Bank of Canada lifted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Friday, July 12th. HC Wainwright lifted their target price on Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, June 18th. Robert W. Baird started coverage on Nurix Therapeutics in a research note on Friday, September 6th. They set an “outperform” rating and a $26.00 target price on the stock. Finally, Truist Financial began coverage on Nurix Therapeutics in a research note on Wednesday, July 31st. They set a “buy” rating and a $36.00 target price on the stock. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.